NVO250103P115000
- 27.70
- 0.000.00%
Novo-Nordisk A/S Newsroom
Novo Nordisk Analyst Ratings
Novo Nordisk Target Cut to DKK750 From DKK1,100 by UBS
Novo Nordisk Raised to Buy From Neutral by UBS
Berenberg Cuts Novo Nordisk's Price Target After 'Disappointing' Weight-loss Drug Trial Results
BMO Capital has lowered the Target Price for Novo-Nordisk A/S to $105.
Major Bank Rating | TD Cowen: Downgraded Novo-Nordisk A/S Target Price to $105, maintaining "Buy" rating.
BMO Capital Maintains Outperform on Novo Nordisk, Lowers Price Target to $105
Novo Nordisk Analyst Ratings
TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Cuts Target Price to $105
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Cuts Target Price to $105
Jefferies Maintains Novo-Nordisk A/S(NVO.US) With Sell Rating, Cuts Target Price to $81.5
CFRA Initiates Novo-Nordisk A/S(NVO.US) With Hold Rating, Announces Target Price $122
TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $155
The Trader: Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop -- Barron's
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $156
Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop -- Barrons.com
BofA Securities Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating
TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Announces Target Price $155
Novo Nordisk Analyst Ratings
TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating